Health
DiosCURE to Develop Highly Specific Single-Chain Antibodies Against SARS-CoV-2, Lead Candidates Described in Science Publication | Antibodies | News Channels – PipelineReview.com
La Merie Publishing prepares brief and full reports as well as competitor analysis reports, the latter in a tabulated format with structured listings of industry-relevant…
Details
Category: Antibodies
Published on Tuesday, 12 January 2021 16:21
Hits: 125
– Core technology includes promising bivalent single-domain antibodies simultaneously targeting two surface structures of the viral spike protein.
– Lead candidates DIOS-202 and DIOS-203 are engineered for high potency and their potential to avoid the emergence of escape mutants.
– DIOS-202 and DIOS-203 entered into accelerated development to initiate clinical studies later this year.
BONN, Germany I January 12,…
-
Business5 hours ago1 ASX dividend stock down 43% I’d buy right now
-
Business9 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
General23 hours agoFederal Labor makes $100m Canberra convention centre funding pledge for planning, new aquatic centre
-
General21 hours agoDonald Trump and the ghost of Al Capone • Inside Story